Stoke TherapeuticsSTOK
STOK
About: Stoke Therapeutics Inc is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine. Its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, Stoke is developing antisense oligonucleotides (ASOs) to restore naturally-occurring protein levels selectively. Its first medicine in development, zorevunersen, has demonstrated the potential for disease modification in patients with Dravet syndrome. The company provides early programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye, to up-regulate the protein expression of the underlying disease gene in a mutation-agnostic manner.
Employees: 128
0
Funds holding %
of 7,323 funds
0
Analysts bullish %
of 3 analysts
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
50% more repeat investments, than reductions
Existing positions increased: 45 | Existing positions reduced: 30
7.59% more ownership
Funds ownership: 109.61% [Q4 2024] → 117.21% (+7.59%) [Q1 2025]
0% more funds holding in top 10
Funds holding in top 10: 3 [Q4 2024] → 3 (+0) [Q1 2025]
7% less first-time investments, than exits
New positions opened: 25 | Existing positions closed: 27
2% less funds holding
Funds holding: 130 [Q4 2024] → 127 (-3) [Q1 2025]
34% less capital invested
Capital invested by funds: $640M [Q4 2024] → $422M (-$219M) [Q1 2025]
94% less call options, than puts
Call options by funds: $60K | Put options by funds: $973K
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$22
71%
upside
Avg. target
$29
125%
upside
High target
$35
172%
upside
3 analyst ratings
3 positive
100%
0 neutral
0%
0 negative
0%
Jefferies Andrew Tsai | 133%upside $30 | Buy Initiated | 18 Jul 2025 |
Needham Joseph Stringer | 71%upside $22 | Buy Reiterated | 1 Jul 2025 |
HC Wainwright & Co. Andrew Fein | 172%upside $35 | Buy Maintained | 14 May 2025 |
Financial journalist opinion
Based on 4 articles about STOK published over the past 30 days
Negative
Zacks Investment Research
6 hours ago
Analysts Estimate Stoke Therapeutics, Inc. (STOK) to Report a Decline in Earnings: What to Look Out for
Stoke Therapeutics (STOK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Neutral
Business Wire
2 weeks ago
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine and has a lead investigational medicine, zorevunersen, in development as a first-in-class potential disease-modifying treatment for Dravet syndrome. The Company today announced that, effective on July 15, 2025, it granted stock options to purchase shares of common stock to Sara Den Besten, the Company's.
Neutral
Business Wire
2 weeks ago
Stoke Therapeutics and Biogen Announce Presentation of Data from Studies of Zorevunersen, an Investigational Medicine for Dravet syndrome, at the 16th European Paediatric Neurology Society (EPNS) Congress
BEDFORD, Mass., & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine, and Biogen Inc. (Nasdaq: BIIB) today announced the presentation of data from an analysis that informed the design of the Phase 3 EMPEROR study and evaluated the potential effects of the Phase 3 zorevunersen dosing regimen. The data are complementary to previously reported data from a.
Neutral
GlobeNewsWire
2 weeks ago
Biogen and Stoke Therapeutics Announce Presentation of Data from Studies of Zorevunersen, an Investigational Medicine for Dravet syndrome, at the 16th European Paediatric Neurology Society (EPNS) Congress
– Data from an analysis designed to evaluate the potential effects of the Phase 3 zorevunersen dosing regimen showed improvements in cognition and behavior at Week 68 – – These findings support the inclusion of key secondary endpoints assessing cognition and behavior in the Phase 3 EMPEROR study and contrast with outcomes observed in natural history data – CAMBRIDGE, Mass. and BEDFORD, Mass.
Neutral
Business Wire
1 month ago
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine and has a lead investigational medicine, zorevunersen, in development as a first-in-class potential disease-modifying treatment for Dravet syndrome. The Company today announced that, effective on June 16, 2025, it granted stock options to purchase an aggregate of 37,200 shares of common stock to two new.
Positive
Seeking Alpha
1 month ago
Stoke Therapeutics: Impressive Pipeline And Big Backers
Stoke Therapeutics is pioneering RNA-based therapies, with a lead candidate for Dravet Syndrome aiming for true disease modification, unlike current symptom-focused treatments. The company's pipeline includes promising programs for SYNGAP-1, Rett syndrome, and ADOA, with industry validation via impressive new partnerships with Biogen and Acadia. Financially, Stoke is buoyed by its new milestone-rich deals, but as a ticker it faces high short interest and high volatility.
Neutral
Business Wire
2 months ago
Stoke Therapeutics to Present at the Jefferies Global Healthcare Conference
BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine and has a lead investigational medicine, zorevunersen, in development as a first-in-class potential disease-modifying treatment for Dravet syndrome. The Company today announced that Interim Chief Executive Officer Ian F. Smith will present at the Jefferies Global Healthcare Conference on Wednesday, June.
Positive
Zacks Investment Research
2 months ago
Wall Street Analysts Think Stoke Therapeutics (STOK) Could Surge 132.4%: Read This Before Placing a Bet
The consensus price target hints at a 132.4% upside potential for Stoke Therapeutics (STOK). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Positive
Zacks Investment Research
2 months ago
Stoke Therapeutics, Inc. (STOK) Tops Q1 Earnings and Revenue Estimates
Stoke Therapeutics, Inc. (STOK) came out with quarterly earnings of $1.90 per share, beating the Zacks Consensus Estimate of a loss of $0.37 per share. This compares to loss of $0.57 per share a year ago.
Neutral
Business Wire
2 months ago
Stoke Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Updates
BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine and has a lead investigational medicine, zorevunersen, in development as a first-in-class potential disease-modifying treatment for Dravet syndrome. The Company today reported financial results for the first quarter ended March 31, 2025, and provided business updates. “The first quarter was defined by s.
Charts implemented using Lightweight Charts™